Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus MEDROL.
HYDELTRASOL vs MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines (e.g., IL-1, IL-2, TNF-alpha). It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
4 to 48 mg orally once daily or every other day, depending on condition. Initial dose may be up to 48 mg/day.
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal half-life of methylprednisolone is 2.5-3.5 hours; for the active metabolite (prednisolone), half-life is 2.1-3.5 hours. Clinical context: Despite short half-life, pharmacodynamic effects persist beyond plasma presence due to receptor-mediated actions.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal (approximately 80-90% as metabolites, <5% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Corticosteroid
Corticosteroid